Inovio Pharmaceuticals (NASDAQ:INO) PT Lowered to $7.00

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective decreased by equities research analysts at Royal Bank of Canada from $8.00 to $7.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective points to a potential upside of 26.13% from the company’s previous close.

A number of other research firms have also commented on INO. HC Wainwright reiterated a “neutral” rating and issued a $15.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, July 15th. Oppenheimer dropped their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Inovio Pharmaceuticals currently has an average rating of “Hold” and an average price target of $43.80.

Inovio Pharmaceuticals Stock Down 1.8 %

Shares of INO stock opened at $5.55 on Friday. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75. The company has a market cap of $143.81 million, a PE ratio of -1.51 and a beta of 0.82. The business’s 50 day moving average is $7.30 and its two-hundred day moving average is $9.42.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 99.51%. During the same quarter in the previous year, the business posted ($1.56) earnings per share. As a group, equities analysts expect that Inovio Pharmaceuticals will post -4.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $82,000. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals in the second quarter valued at about $88,000. SG Americas Securities LLC acquired a new position in Inovio Pharmaceuticals in the third quarter worth about $71,000. Cornercap Investment Counsel Inc. bought a new position in Inovio Pharmaceuticals during the second quarter worth about $184,000. Finally, American Century Companies Inc. boosted its holdings in Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.